Serum sodium, renal function, and survival of patients with end-stage liver disease
Authors:
- 1 April 2010
- journal article
- Published by Elsevier in Journal of Hepatology
- Vol. 52 (4) , 523-528
Abstract
No abstract availableKeywords
This publication has 41 references indexed in Scilit:
- Effects of satavaptan, a selective vasopressin V2 receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremiaHepatology, 2008
- Formula estimation of glomerular filtration rate: have we gone wrong?BMJ, 2007
- MELD score and serum sodium in the prediction of survival of patients with cirrhosis awaiting liver transplantationGut, 2007
- Evidence-based evolution of the MELD/PELD liver allocation policyLiver Transplantation, 2005
- Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early deathHepatology, 2004
- Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early deathHepatology, 2004
- Inappropriately low angiotensin II generation: a factor determining reduced kidney function and survival in patients with decompensated cirrhosisJournal of Hepatology, 2004
- Assessing renal function in cirrhotic patients: Problems and pitfallsAmerican Journal of Kidney Diseases, 2003
- Pathophysiology of renal disease associated with liver disorders: Implications for liver transplantation. Part ILiver Transplantation, 2002
- A Model to Predict Survival in Patients With End–Stage Liver DiseaseHepatology, 2001